The University of Chicago Header Logo

Connection

Anand Patel to Humans

Back to Details
This is a "connection" page, showing publications Anand Patel has written about Humans.
Anand Patel
Connection Strength
0.813
Humans
  1. Contemporary data in myeloproliferative neoplasm-unclassifiable: mutational landscape and management of the 'unclassifiable'. Curr Opin Hematol. 2026 Mar 01; 33(2):45-50.
    View in: PubMed
    Score: 0.031
  2. SOHO State of the Art Updates and Next Questions | Challenging Scenarios in the Management of Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2025 Jul; 25(7):484-493.
    View in: PubMed
    Score: 0.029
  3. Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia. Haematologica. 2025 Apr 01; 110(4):828-839.
    View in: PubMed
    Score: 0.029
  4. Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia. Blood Adv. 2024 09 10; 8(17):4647-4650.
    View in: PubMed
    Score: 0.028
  5. Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era. Blood Adv. 2024 07 09; 8(13):3468-3477.
    View in: PubMed
    Score: 0.028
  6. Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome. Curr Treat Options Oncol. 2024 Jun; 25(6):752-768.
    View in: PubMed
    Score: 0.028
  7. Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 Jun; 65(6):864-867.
    View in: PubMed
    Score: 0.027
  8. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024 Apr; 204(4):1238-1242.
    View in: PubMed
    Score: 0.027
  9. Novel Therapies in Myelodysplastic Syndrome: Where Do Venetoclax and Isocitrate Dehydrogenase Inhibitors Fit in? Cancer J. 2023 May-Jun 01; 29(3):188-194.
    View in: PubMed
    Score: 0.026
  10. Targeted Therapy for MPNs: Going Beyond JAK Inhibitors. Curr Hematol Malig Rep. 2023 06; 18(3):41-55.
    View in: PubMed
    Score: 0.025
  11. SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It. Clin Lymphoma Myeloma Leuk. 2023 05; 23(5):303-309.
    View in: PubMed
    Score: 0.025
  12. The Cup Runneth Over: Treatment Strategies for Newly Diagnosed Acute Myeloid Leukemia. JCO Oncol Pract. 2023 02; 19(2):74-85.
    View in: PubMed
    Score: 0.025
  13. Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. JCO Precis Oncol. 2022 10; 6:e2200353.
    View in: PubMed
    Score: 0.025
  14. Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy. Blood Adv. 2021 10 26; 5(20):4140-4148.
    View in: PubMed
    Score: 0.023
  15. Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies. Blood Adv. 2021 04 27; 5(8):2264-2271.
    View in: PubMed
    Score: 0.022
  16. Paraneoplastic Thrombocytopenia. Am J Med. 2021 08; 134(8):976-979.
    View in: PubMed
    Score: 0.022
  17. Genomics of MPN progression. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):440-449.
    View in: PubMed
    Score: 0.022
  18. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib. Curr Hematol Malig Rep. 2020 12; 15(6):409-418.
    View in: PubMed
    Score: 0.022
  19. Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults. Curr Treat Options Oncol. 2020 05 28; 21(7):57.
    View in: PubMed
    Score: 0.021
  20. Clinical and Biological Prognostic Factors in Follicular Lymphoma. Hematol Oncol Clin North Am. 2020 08; 34(4):647-662.
    View in: PubMed
    Score: 0.021
  21. Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51.
    View in: PubMed
    Score: 0.021
  22. Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias. Blood Adv. 2026 Mar 10; 10(5):1746-1755.
    View in: PubMed
    Score: 0.008
  23. Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms. Blood Adv. 2026 Mar 10; 10(5):1603-1613.
    View in: PubMed
    Score: 0.008
  24. Impact of modernizing eligibility criteria on enrollment and representation in acute myeloid leukemia clinical trials. Blood. 2026 Feb 05; 147(6):639-649.
    View in: PubMed
    Score: 0.008
  25. Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with =5% blasts: An International TP53 Investigators Network (iTiN) study. Cancer. 2026 Jan 01; 132(1):e70210.
    View in: PubMed
    Score: 0.008
  26. Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J. 2025 Aug 14; 15(1):138.
    View in: PubMed
    Score: 0.008
  27. Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Haematologica. 2026 Jan 01; 111(1):158-167.
    View in: PubMed
    Score: 0.008
  28. Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutations. Blood Adv. 2025 Jul 22; 9(14):3395-3407.
    View in: PubMed
    Score: 0.008
  29. Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax?+?Hypomethylating Agent. Am J Hematol. 2025 Feb; 100(2):260-271.
    View in: PubMed
    Score: 0.007
  30. A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis. Blood Adv. 2024 11 26; 8(22):5735-5743.
    View in: PubMed
    Score: 0.007
  31. Somatic co-alteration signatures are prognostic in high-grade TP53-mutated myeloid neoplasms. Br J Haematol. 2025 Apr; 206(4):1103-1108.
    View in: PubMed
    Score: 0.007
  32. Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood. 2024 Nov 07; 144(19):2033-2044.
    View in: PubMed
    Score: 0.007
  33. Prognostic impact of 'multi-hit' versus 'single-hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases. Haematologica. 2024 11 01; 109(11):3533-3542.
    View in: PubMed
    Score: 0.007
  34. Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis. Blood. 2024 10 24; 144(17):1813-1820.
    View in: PubMed
    Score: 0.007
  35. Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study. Am J Hematol. 2024 Dec; 99(12):2388-2391.
    View in: PubMed
    Score: 0.007
  36. Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 06 18; 14(1):99.
    View in: PubMed
    Score: 0.007
  37. NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024. J Natl Compr Canc Netw. 2024 06; 22(2 D).
    View in: PubMed
    Score: 0.007
  38. Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 May 01; 5(3):164-179.
    View in: PubMed
    Score: 0.007
  39. Transfusion management and hemoglobin-based oxygen carrier treatment in a patient with anti-Rh17 antibody. Transfusion. 2024 06; 64(6):1161-1166.
    View in: PubMed
    Score: 0.007
  40. Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia. Haematologica. 2024 04 01; 109(4):1046-1052.
    View in: PubMed
    Score: 0.007
  41. Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood Cancer J. 2024 02 20; 14(1):32.
    View in: PubMed
    Score: 0.007
  42. Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leuk Lymphoma. 2024 Jan; 65(1):69-77.
    View in: PubMed
    Score: 0.007
  43. Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
    View in: PubMed
    Score: 0.007
  44. Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity. Nature. 2023 11; 623(7989):1034-1043.
    View in: PubMed
    Score: 0.007
  45. Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia. Blood Adv. 2023 11 14; 7(21):6492-6505.
    View in: PubMed
    Score: 0.007
  46. Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia. Clin Cancer Res. 2023 08 15; 29(16):3151-3161.
    View in: PubMed
    Score: 0.007
  47. Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.
    View in: PubMed
    Score: 0.007
  48. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia. 2023 04; 37(4):799-806.
    View in: PubMed
    Score: 0.006
  49. Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. Cancer. 2023 03 15; 129(6):934-945.
    View in: PubMed
    Score: 0.006
  50. Structural racism is a mediator of disparities in acute myeloid leukemia outcomes. Blood. 2022 04 07; 139(14):2212-2226.
    View in: PubMed
    Score: 0.006
  51. Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. Am J Hematol. 2022 07; 97(7):E232-E235.
    View in: PubMed
    Score: 0.006
  52. Over the Threshold: an Exercise in Clinical Reasoning. J Gen Intern Med. 2022 04; 37(5):1290-1294.
    View in: PubMed
    Score: 0.006
  53. Provider-Level Barriers to Human Papillomavirus Vaccination in Survivors of Childhood and Young Adult Cancers. J Adolesc Young Adult Oncol. 2022 06; 11(3):284-289.
    View in: PubMed
    Score: 0.006
  54. The Phantom Menace: Immunodeficiency-Associated Disease in an Immunocompetent Patient. Am J Med. 2021 12; 134(12):1555-1557.
    View in: PubMed
    Score: 0.006
  55. Impact of race on outcomes in intermediate-risk acute myeloid leukemia. Cancer Causes Control. 2021 Jul; 32(7):705-712.
    View in: PubMed
    Score: 0.006
  56. Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. Bone Marrow Transplant. 2021 08; 56(8):1998-2004.
    View in: PubMed
    Score: 0.006
  57. Left Out in the Cold. J Hosp Med. 2021 02; 16(2):105-108.
    View in: PubMed
    Score: 0.006
  58. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021 04 01; 127(7):1039-1048.
    View in: PubMed
    Score: 0.005
  59. Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement. Blood Adv. 2020 10 13; 4(19):4924-4928.
    View in: PubMed
    Score: 0.005
  60. The genealogy of teaching clinical reasoning and diagnostic skill: the GEL Study. Diagnosis (Berl). 2020 08 27; 7(3):197-203.
    View in: PubMed
    Score: 0.005
  61. Peabody's Paradox: Balancing Patient Care and Medical Education in a Pandemic. J Grad Med Educ. 2020 Jun; 12(3):264-268.
    View in: PubMed
    Score: 0.005
  62. Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Adv. 2020 05 26; 4(10):2308-2316.
    View in: PubMed
    Score: 0.005
  63. The Socrates Project for Difficult Diagnosis at Northwestern Medicine. J Hosp Med. 2020 02 01; 15(2):116-118.
    View in: PubMed
    Score: 0.005
  64. FOXM1 contributes to treatment failure in acute myeloid leukemia. JCI Insight. 2018 08 09; 3(15).
    View in: PubMed
    Score: 0.005
  65. Insight into Sweet's syndrome and associated-malignancy: a review of the current literature. Int J Oncol. 2013 May; 42(5):1516-22.
    View in: PubMed
    Score: 0.003
  66. Sequence requirements for combinatorial recognition of histone H3 by the MRG15 and Pf1 subunits of the Rpd3S/Sin3S corepressor complex. J Mol Biol. 2012 Sep 28; 422(4):519-31.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.